JB Pharma strengthens its position in Gastroenterology with launch of RANRAFT

Mumbai: Gastroesophageal reflux disease (GERD), affects up to 1 in 5 Indian patients, causes heartburn, acid reflux and impacts the quality of life. It is worsened with the consumption of certain non-vegetarian food, spices, tobacco consumption etc.

Hence, in this endeavour, JB Pharma, makers of the popular drug Rantac strengthens its presence in the area of gastroenterology, by launching a unique formulation called RANRAFT to provide quick relief by neutralizing acid and preventing acid reflux.

The oral suspension Ranraft contains Sodium alginate 250 mg, Sodium bicarbonate 133.5 mg, and Calcium Carbonate 80 mg per 5ml. Sodium alginate in Ranraft helps to prevent acid reflux by forming a raft which floats on the stomach contents whereas sodium bicarbonate & calcium carbonate neutralizes the stomach acid.

This dual action of Ranraft is aimed at providing rapid and long-lasting relief up to 4 hours which is 2 times longer than conventional antacids.

"Currently most conventional antacids available in the market do not prevent acid reflux. However, Ranraft oral suspension with its unique mechanism of action not only prevents acid reflux but also provides quick and lasting relief for up to 4 hours," said Mr. Dilip Singh Rathore, President-India Business, JB Pharma.

"Ranraft oral suspension is indicated in heartburn and indigestion for use in patients with post prandial acid reflux, regurgitation-dominant GERD, severe or PPI-unresponsive GERD and can also be used during pregnancy, if clinically indicated." added Dr Kapil Mehta, Head-Medical, JB Pharma.

Known for its popular brands including Rantac, Metrogyl, Sporlac, Cilacar and Nicardia, the company, JB Pharma is one of fastest-growing pharmaceutical companies in India.